ReviewJournal of fungi (Basel, Switzerland)2023
Review in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 109 citations in OpenAlex.
- Biological Evaluation of Two Magnesium Alloys from Mg-Zn-Mn-Ca and Mg-Nd-Y-Zr-Zn Systems for Bone Repair and Regeneration.Journal of functional biomaterials · 2026Article
- Contrasting Biofilm-Modulating Effects of Polymeric Quaternary Ammonium Compounds on the Pathogenic YeastsACS omega · 2026Article
- Discovery of an Internal α-1,3-Linkage-Containing Manno-Oligosaccharide in theMicroorganisms · 2026Article
- The metabolic trap:Journal of medical microbiology · 2026Article
- Identification of Clinically Relevant Yeasts from Avian Isolates Using API ID32C, MALDI-TOF MS, and ITS Sequencing: Potential Relevance from a One Health Perspective.Veterinary sciences · 2026Article
- Shift in Candidemia Epidemiology and Emerging Fluconazole Resistance inJournal of fungi (Basel, Switzerland) · 2026Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Genomic Characterization of Candida spp. Highlights a Persistent, Azole-Resistant C. parapsilosis Clone Circulating in a Tertiary Care Hospital During the First COVID-19 Wave.Mycopathologia · 2026Article
- Candidemia in Southern Poland (2017-2022): Multicenter Analysis of Species Distribution and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2026Article
- We Are Family: Comparative Study ofPathogens (Basel, Switzerland) · 2026Article
- Purification and characterization of a dihydroxy Oxocyclohexyl acetate derivative from endophytic Aspergillus Candidus targeting Candida albicans lanosterol 14α-Demethylase.Scientific reports · 2026Article
- Targeting polymicrobial skin infections in atopic dermatitis: role ofFrontiers in microbiology · 2026Article
- Six-month surveillance ofFrontiers in cellular and infection microbiology · 2026Article
- The fungal stronghold: biofilms in hemodialysis catheters, diagnostic pitfalls, and the challenge of catheter salvage.Frontiers in cellular and infection microbiology · 2026Review
- Secretion of serine proteases by planktonic- and biofilm-growing cells of Candida parapsilosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Changes in microbial communities during the spoilage of palm wine stored at room temperature.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Fungal Prosthetic Joint Infection byAntibiotics (Basel, Switzerland) · 2025Article
- Genome sequences of six clinical isolates ofMicrobiology resource announcements · 2025Article
- Clinical impact of fluconazole-resistantFuture microbiology · 2025Review
- Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Candida parapsilosis is the second most common Candida species isolated in Asia, Southern Europe, and Latin America and is often involved in invasive infections that seriously impact human health. This pathogen is part of the psilosis complex, which also includes Candida orthopsilosis and Candida metapsilosis. C. parapsilosis infections are particularly prevalent among neonates with low birth weights, individuals who are immunocompromised, and patients who require prolonged use of a central venous catheter or other indwelling devices, whose surfaces C. parapsilosis exhibits an enhanced capacity to adhere to and form biofilms. Despite this well-acknowledged prevalence, the biology of C. parapsilosis has not been as extensively explored as that of Candida albicans. In this paper, we describe the molecular mechanistic pathways of virulence in C. parapsilosis and show how they differ from those of C. albicans. We also describe the mode of action of antifungal drugs used for the treatment of Candida infections, namely, polyenes, echinocandins, and azoles, as well as the resistance mechanisms developed by C. parapsilosis to overcome them. Finally, we stress the importance of the ongoing search for species-specific features that may aid the development of effective control strategies and thus reduce the burden on patients and healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.